Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vunakizumab - Jiangsu Hengrui Medicine

Next Previous
X
Search
Drug Profile

Vunakizumab - Jiangsu Hengrui Medicine

Alternative Names: IL-17A antagonist - Jiangsu Hengrui Medicine; SHR 1314

Latest Information Update: 19 Nov 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Jiangsu Hengrui Medicine Co.
  • Developer Jiangsu Hengrui Medicine Co.; Suzhou Suncadia Biopharmaceuticals
  • Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action IL17A protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Plaque psoriasis
  • Preregistration Ankylosing spondylitis
  • Phase III Psoriatic arthritis
  • Phase II Graves ophthalmopathy

Most Recent Events

  • 04 Nov 2024 Phase-III clinical trials in Psoriatic arthritis in China (SC) (NCT06640257)
  • 15 Oct 2024 Suzhou Suncadia Biopharmaceuticals plans a phase III trial for Psoriatic arthritis in China (Injection) (NCT06640257)
  • 02 Sep 2024 Efficacy and adverse events data from a phase III trial in Plaque psoriasis released by Jiangsu HengRui Medicine

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top